title: Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?
abstract: Prostate cancer and its management have been intensely debated for years. Recommendations range from ardent support for active screening and immediate treatment to resolute avoidance of screening and active surveillance. There is a growing body of level I evidence establishing a clear survival advantage for treatment of subsets of patients with clinically localized prostate cancer. This chapter presents a review of these randomized controlled trials. We argue that an understanding of this literature is relevant not only to those considering active surveillance but also to those evaluating the merits of screening. In addition, a number of important evidence-based conclusions concerning what should and should not be done can be gleaned from these trials.
authors.affiliation: UCSF-Helen Diller Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1708, USA. mroach@radonc.ucsf.edu
authors.forename: Mack
authors.initials: M
authors.lastname: Roach
authors.forename: Kimberly
authors.initials: K
authors.lastname: Thomas
mesh_terms: D026683:Advisory Committees; D019468:Disease Management; D055088:Early Detection of Cancer; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000532:radiotherapy / Q000628:therapy*; D015996:Survival Rate; D014481:United States; D057832:Watchful Waiting
chemical_list: D017430:Prostate-Specific Antigen